Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade

Journal for Immunotherapy of Cancer
Xiaoliang LiuYu Li

Abstract

Late-stage or recurrent intrahepatic cholangiocarcinoma (ICC) patients exhibit poor prognosis due to limited sensitivity to chemotherapy or radiotherapy and coexistence of multiple lesions. Programmed cell death protein 1 (PD-1) blockade provides a therapeutic opportunity for patients with high tumor mutation burden (TMB), high microsatellite instability (MSI-H), deficient mismatch repair (dMMR) and/or positive programmed cell death ligand 1 (PD-L1) expression. However, it is currently believed that patients with low TMB, microsatellite stable (MSS), proficient mismatch repair (pMMR) or negative PD-L1 expression are less likely to benefit from PD-1 blockade. Here we provide the first report on the therapeutic responses of ICC patients treated with combined PD-1 blockade with stereotactic body radiotherapy (SBRT) (Cyberknife) in the background of low TMB, MSS, pMMR and negative PD-L1 expression. One stage IVA ICC patients and two postsurgical recurrent ICC patients were involved in this study and the responses of both locally irradiated tumor(s) and the abscopal tumors or metastasis to the combined therapy were assessed by magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT). The stage I...Continue Reading

References

May 4, 1999·Japanese Journal of Clinical Oncology·M YamamotoT Yoshikawa
Jun 12, 2004·Seminars in Liver Disease·Yasser Shaib, Hashem B El-Serag
Mar 9, 2012·The New England Journal of Medicine·Michael A PostowJedd D Wolchok
Aug 20, 2014·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Jian-Qiang CaiWei-Ping Zhou
Jun 20, 2015·Gastroenterology Research and Practice·Kelly J LafaroTimothy M Pawlik
Jul 15, 2015·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Sharon M WeberTimothy M Pawlik
Oct 31, 2015·Journal of Cancer·Anand MahadevanAmy Evenson
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naiyer A RizviScott Antonia
May 11, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick A OttJean-Charles Soria
Jul 12, 2017·Critical Reviews in Oncology/hematology·Michela SquadroniRoberto Labianca
Dec 28, 2017·Internal Medicine·Yuko Harada, Shinichiro Miyazaki
Jan 23, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J OvermanThierry André
Feb 2, 2018·American Journal of Clinical Oncology·Francesco FioricaAntonio Frassoldati
Feb 14, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason J LukeSteven J Chmura
Feb 23, 2018·Annals of Hepatology·Telma Erotides da SilvaLeonardo de Lucca Schiavon

❮ Previous
Next ❯

Citations

Aug 25, 2020·Bioscience Trends·Wei ZhangQiang Li
Jan 8, 2020·Cancers·Julijan KabiljoMichael Bergmann
Aug 13, 2020·Cancers·Erta KalanxhiAnne Hansen Ree
Oct 24, 2020·Cancer Immunology, Immunotherapy : CII·Wei Zhang QiangLi
Nov 25, 2020·World Journal of Surgical Oncology·Lingyu TianXiaoying Wang
Jan 1, 2021·Expert Opinion on Investigational Drugs·Arndt VogelAnna Saborowski
Oct 17, 2020·Translational Oncology·Wei HuangYue-Can Zeng
Mar 20, 2021·OncoTargets and Therapy·Poshita-Kumari SeesahaXiao-Feng Chen
Sep 17, 2021·Technology in Cancer Research & Treatment·Fan-Li Zeng, Jing-Fang Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
surgical resection

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.